Abstract:2564 Background: Use of tumor antigens for the development of patient-specific cancer vaccines has been a promising therapeutic strategy. However, challenges remain in delivering subunit vaccine components in a coordinated fashion to elicit antitumor immune responses. To overcome these, we developed rationally designed vaccines using a novel nanoplatform called the Protein-Like Polymer (PLP), in reference to its globular structure reminiscent of native proteins, with unique characteristics that allow for sustained/targeted delivery of tumor antigens in conjunction with STING agonists. Methods: PLPs containing a model melanoma antigen were synthesized via ring-opening metathesis polymerization (ROMP) and characterized. A library of compounds were generated with different sidechain linkage chemistries (amide, ester, or disulfide), degrees of polymerization, and inclusion/exclusion of Oligo(ethylene glycol) (OEG) side chains. In vitro uptake and functional assays using gp100-specific T Cells were conducted with fluorescently-labeled and non-labeled polymers respectively. In vivo experiments were done using a B16F10 murine melanoma tumor model over-expressing gp100. Ability of PLPs to co-deliver immunomodulatory compounds was tested by electrostatically coupling a small molecule STING agonist 2’3’ cGAMP which formed stable nanostructures. The optimized construct was also tested in an OVA system to prove generalizability. Results: Conjugating peptide antigens using a cleavable disulfide linkage, which reduces intracellularly in antigen presenting cells (APCs), resulted in increased endosomal localization and efficacy. Incorporating a diluent amount of OEG side chains increased resistance to enzymatic degradation while improving bioactivity and uptake by APCs. In vivo studies using PLPs conjugated with gp100 resulted in significant increases in survival time and reduced tumor burden in B16 melanoma. Increasing the DP, and therefore the density of antigen side chains, improved vaccine efficacy and resistance to proteolysis. Mice treated with STING-PLP complexes showed significantly smaller tumors vs control at day 14 (0.038g vs 0.76g; p < 0.0001) and allowed for subcutaneous administration of 2’3’ cGAMP, which otherwise diffuses rapidly away from the injection site. OVA-PLPs behaved similarly in their cognate system but showed no activity when tested on gp100-specific cells and vice versa demonstrating antigen-specificity. Conclusions: This work validates the potential of PLPs to overcome major limitations in cancer vaccine development. The modularity of the platform allows for complex nano-architectures including systems capable of delivering challenging compounds, ie small molecule STING agonists, subcutaneously through electrostatic coupling. This technology has the potential to revolutionize cancer vaccinology.

Effective oral delivery of gp100 plasmid vaccine against metastatic melanoma through multi-faceted blending-by-blending nanogels.

A Novel Polymeric Peptide Delivery Platform and Association with Targeted Co-Delivery of Antigens and STING Agonists with Antitumor Immune Response.

Erythrocyte Membrane-Enveloped Polymeric Nanoparticles As Nanovaccine for Induction of Antitumor Immunity Against Melanoma

Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response

The Expression and Protective Efficacy of DNA Vaccine Encoding Antibodized Hgp100

PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses

A laponite-based immunologically active gel delivery system for long-acting tumor vaccine

Bio-membrane Adhesive Poly(choline Phosphate L-glutamate)-based Nanoparticles As Vaccine Delivery Systems for Cancer Immunotherapy

Enhanced Immune Response to Gastric Cancer Specific Antigen Peptide by Coencapsulation with CpG Oligodeoxynucleotides in Nanoemulsion

Use of a novel proteomimetic nanoplatform for simultaneous delivery of antigens with adjuvants to impact tumor growth in multiple tumor models.

Human gp100 induces specific anti- murine melanoma immune response, implicating a potential way to antitumor immunotherapy

Preparation of a New Gastric Cancer Specific Nanovaccine and Study of Its Bioactivity

A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy

Delivery System of Cpg Oligodeoxynucleotides Through Eliciting an Effective T Cell Immune Response Against Melanoma in Mice

Use of Proteomimetic Polymers for Delivery of Tumor Antigens and Adjuvants Through Formation of Stable Electrostatic Complexes with Small Molecule STING Agonists

Nanovaccine Based on a Protein-Delivering Dendrimer for Effective Antigen Cross-Presentation and Cancer Immunotherapy

A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumors via a full-cycle immunomodulation

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growth

“Double-punch” strategy for delivery of viral immunotherapy with prolonged tumor retention and enhanced transfection efficacy

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.